

DOCKET NO.: CSKL0003-100**PATENT****In the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 26, 28 and 29, and add new claims 30-35 as set forth below.

1-25. (cancelled).

26. (currently amended) A method of inhibiting cell division comprising contacting a cell with an effective amount of 3-iodoacetamido benzoyl ethyl ester (3-IAABE), wherein the cell is selected from a leukemia cancer cell, a melanoma cancer cell, a renal cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a colon cancer cell, a prostate cancer cell, and a lymphoma cancer cell.

27. (previously presented) The method of claim 26 wherein the cell is contacted with 0.005 to 0.51 µg/ml of 3-IAABE.

28. (currently amended) The method of claim 26 wherein the cell is a prostate cancer cell, ~~a fungal cell, a helminth cell, a cell involved in restenosis, or a cell involved in gout.~~

29. (currently amended) The method of ~~claim 28~~ claim 26 wherein the cancer cell is a T-cell leukemia cell, a cell involved in myelodysplasia syndrome, a melanoma cell, a renal cancer cell, a breast cancer cell, a non-small cell lung cancer cell, a colon cancer cell, or a lymphoma cancer cell.

30. (new) The method of claim 26 wherein the cell is a colon cancer cell.

31. (new) The method of claim 26 wherein the cell is a non-small cell lung cancer cell.

32. (new) The method of claim 26 wherein the cell is a breast cancer cell.

DOCKET NO.: CSKL0003-100**PATENT**

- 33. (new) The method of claim 26 wherein the cell is a renal cancer cell.
- 34. (new) The method of claim 26 wherein the cell is a melanoma cancer cell.
- 35. (new) The method of claim 26 wherein the cell is a leukemia cancer cell.